SCHEMBL4352303

SCHEMBL4352303

CC(C)(C)C(O)CCCNC(=O)O

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 2/20 0.43
KMT2A Q03164 2/20 0.43
GAA P10253 1/20 0.43
PTGS1 P23219 1/20 0.37
KCNH2 Q12809 1/20 0.37
CYP2D6 P10635 1/20 0.35
CYP2C19 P33261 1/20 0.35
TSHR P16473 1/20 0.34
KDM4C Q9H3R0 1/20 0.32
ACACB O00763 1/20 0.32
ACACA Q13085 1/20 0.32
KDM4E B2RXH2 1/20 0.32
MAPK1 P28482 1/20 0.32
HIF1A Q16665 1/20 0.32
SMN1; SMN2 Q16637 2/20 0.32
POLB P06746 2/20 0.32
ALDH1A1 P00352 2/20 0.31
OTC P00480 1/20 0.31
DPP7 Q9UHL4 1/20 0.31
KISS1R Q969F8 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4885972 0.88 CYP2D6 (0.38) MEN1KMT2AGAAPTGS1KCNH2
SCHEMBL838139 0.78 MEN1 (0.42) MEN1KMT2AGAAPTGS1KCNH2
SCHEMBL3020262 0.77 MEN1 (0.45) MEN1KMT2AGAAPTGS1KCNH2
SCHEMBL2846868 0.77 ALDH1A1 (0.48) MEN1KMT2AGAAPTGS1KCNH2
SCHEMBL24829495 0.74 ALDH1A1 (0.59) MEN1KMT2APTGS1KCNH2TSHR
SCHEMBL6720432 0.74 CYP2D6 (0.52) MEN1KMT2AGAACYP2D6CYP2C19
SCHEMBL2460635 0.74 CYP2D6 (0.52) CYP2D6CYP2C19TSHR
SCHEMBL3856822 0.73 GPR84 (0.38) MEN1KMT2AGAACYP2D6CYP2C19
SCHEMBL17632320 0.73 DPP7 (0.40) MEN1KMT2AGAACYP2D6CYP2C19
SCHEMBL1003535 0.73 MEN1 (0.38) MEN1KMT2AGAAPTGS1KCNH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8455497-B2 Inhibitors of aspartyl protease VERTEX PHARMACEUTICALS INCORPORATED (US) 2013-06-04 US disclosed
US-20090274650-A1 INHIBITORS OF ASPARTYL PROTEASE VERTEX PHARMACEUTICALS INCORPORATED 2009-11-05 US disclosed
EP-1194404-A1 INHIBITORS OF ASPARTYL PROTEASE Vertex Pharmaceuticals Incorporated (US) 2002-04-10 EP disclosed
WO-2000076961-A1 INHIBITORS OF ASPARTYL PROTEASE VERTEX PHARMACEUTICALS INCORPORATED (US) 2000-12-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090274650-A1 INHIBITORS OF ASPARTYL PROTEASE SPINT2, DNPEP, PRSS1 MEN1 4418/4885KMT2A 864/4885GAA 131/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.